BP001309-PRO-337: Recombinant Human Beta-2-Microglobulin (B2M) Protein
Source: E. coli-derived.
Purity: > 95.0% by RP-HPLC and SDS-PAGE.BP001309-PRO-553: Human Beta-2-Microglobulin (B2M) Protein
Source: Human urine from patients with tubular proteinuria-derived.
Purity: > 98.0%.BP001309-PRO-859: Recombinant Human Beta-2-Microglobulin (B2M) Protein, His Tag
Source: E. coli-derived.
Purity: > 95.0% by SDS-PAGE.APIM050405: Batefenterol (GSK-961081, TD-5959)
CAS No.: 743461-65-6
Purity: >98% (or refer to the Certificate of Analysis)
QC: Achiral and Chiral HPLCs, MS, NMR, and Quantitative Elemental Analysis Report
Solubility: Soluble in DMSOBP001237-C103: Recombinant Human Bcl-2 related protein A1 (BCL2A1) Protein
Source: E. coli-derived.
Purity: > 95% by SEC-HPLC and reducing SDS-PAGE.
Endotoxin: < 0.1 ng/ug (1 IEU/ug).BP001237-PRO-1102: Recombinant Human BCL2-Related Protein A1 (BCL2A1) Protein
Source: E. coli-derived.
Purity: > 95% by SDS-PAGE.C041P: Briakinumab Biosimilar, IL-12 / IL-23 Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade briakinumab biosimilar specifically binds to the human interleukin-12 (IL-12) and interleukin-23 (IL-23).
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by briakinumab.BP001633-C304: Recombinant Human Complement C1q Tumor Necrosis Factor-Related Protein 1 (C1qTNF1)
Source: HEK 293-derived.
Purity: > 95% by SEC-HPLC and reducing SDS-PAGE.
Endotoxin: < 0.1 ng/ug (1 IEU/ug).BP001633-PRO-654: Recombinant Human Complement C1q Tumor Necrosis Factor-Related Protein 1 (C1qTNF1)
Source: E. coli-derived.
Purity: > 95% by SDS PAGE.BP001916-PRO-555: Human Complement Component C3c (C3c) Protein
Source: Human Plasma-derived.
Purity: > 96.0%.